The mission of the NYU Cancer Institute is to decrease and eliminate cancer as a significant health problem throughout New York, the nation, and the world, by developing and maintaining excellent programs in patient care, research, education, and prevention.
The NYU Cancer Institute, an NCI designated center since 1975, is a "matrix cancer center," without walls operating within the larger NYU Medical Center. With over 250 members and a research funding base of over $80 million, this structure strengthens our capabilities to forge collaborations across medical and scientific disciplines, which translates to comprehensive care for our patients and discoveries that will influence the future of this disease. The NYU Clinical Cancer Center, with over 60 faculty from various disciplines at the NYU School of Medicine, is the principal outpatient facility of the Cancer Institute, serves as home for our patients and their caregivers. The center and its multi-disciplinary team of experts provide access to the latest treatment options and clinical trials along with a variety of programs in cancer prevention, screening, diagnostics, genetic counseling, and supportive services. Our affiliation with Bellevue Hospital, the oldest public hospital in the country, affords clinically distinctive opportunities to learn and care for patients with cancer by observing its presentation and behavior in a variety of patient groups.
The Cancer Institute specializes in translational research programs that bridge clinical, early detection and diagnosis, treatment, and research in four specialized areas: melanoma, immunotherapy, genitourinary cancers, and breast cancer; thoracic oncology and neuro-oncology are currently under development. Additional initiatives are emerging in the areas of gastrointestinal and gynecologic cancers. The Institute further focuses on more basic research programs in growth control, cancer immunology, stem cell biology, cancer neurobiology, environmental and molecular carcinogenesis, and cancer epidemiology. A select group of our dedicated core facilities is unique to many other cancer centers and supports our translational programs. They include a new class 10,000 vaccine facility, clinical proteomics, tissue acquisition and banking, genomics, and experimental animal and exposure core. To support these initiatives, the Cancer Institute continues its recruitment efforts with a campaign to recruit up to ten new highly skilled researchers and physician scientists to the Smilow Translational Research Center. These scientists will forge new technologies to prevent, diagnose and treat cancers.
|
